Lipid Alteration Signature in the Blood Plasma of Individuals With Schizophrenia, Depression, and Bipolar Disorder
Authors: Anna Tkachev, Elena Stekolshchikova, Anna Vanyushkina, Hanping Zhang, Anna Morozova, Svetlana Zozulya, Ilia Kurochkin, Nickolay Anikanov, Alina Egorova, Ekaterina Yushina, Thomas Vogl, Fanny Senner, Sabrina K. Schaupp, Daniela Reich-Erkelenz, Sergi Papiol, Mojtaba Oraki Kohshour, Farahnaz Klöhn-Saghatolislam, Janos L. Kalman, Urs Heilbronner, Maria Heilbronner, Katrin Gade, Ashley L. Comes, Monika Budde, Heike Anderson-Schmidt, Kristina Adorjan, Jens Wiltfang, Eva Z. Reininghaus, Georg Juckel, Udo Dannlowski, Andreas Fallgatter, Carsten Spitzer, Max Schmauß, Martin von Hagen, Yana Zorkina, Alexander Reznik, Aleksandra Barkhatova, Roman Lisov, Nikita Mokrov, Maxim Panov, Dmitri Zubkov, Daria Petrova, Chanjuan Zhou, Yiyun Liu, Juncai Pu, Peter Falkai, Georgiy Kostyuk, Tatiana Klyushnik, Thomas G. Schulze, Peng Xie, Eva C. Schulte, Philipp Khaitovich
Journal: JAMA Psychiatry (2023)

Importance No clinically applicable diagnostic test exists for severe mental disorders. Lipids harbor potential as disease markers. Objective To define a reproducible profile of lipid alterations in the blood plasma of patients with schizophrenia (SCZ) independent of demographic and environmental variables and to investigate its specificity in association with other psychiatric disorders, ie, major depressive disorder (MDD) and bipolar disorder (BPD). Design, Setting, and Participants This was a multicohort case-control diagnostic analysis involving plasma samples from psychiatric patients and control individuals collected between July 17, 2009, and May 18, 2018. Study participants were recruited as consecutive and volunteer samples at multiple inpatient and outpatient mental health hospitals in Western Europe (Germany and Austria [DE-AT]), China (CN), and Russia (RU). Individuals with DSM-IV or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnoses of SCZ, MDD, BPD, or a first psychotic episode, as well as age- and sex-matched healthy controls without a mental health–related diagnosis were included in the study. Samples and data were analyzed from January 2018 to September 2020. Main Outcomes and Measures Plasma lipidome composition was assessed using liquid chromatography coupled with untargeted mass spectrometry. Results Blood lipid levels were assessed in 980 individuals (mean [SD] age, 36 [13] years; 510 male individuals [52%]) diagnosed with SCZ, BPD, MDD, or those with a first psychotic episode and in 572 controls (mean [SD] age, 34 [13] years; 323 male individuals [56%]). A total of 77 lipids were found to be significantly altered between those with SCZ (n = 436) and controls (n = 478) in all 3 sample cohorts. Alterations were consistent between cohorts (CN and RU: [Pearson correlation] r = 0.75; DE-AT and CN: r = 0.78; DE-AT and RU: r = 0.82; P &amp;amp;lt; 10 −38 ). A lipid-based predictive model separated patients with SCZ from controls with high diagnostic ability (area under the receiver operating characteristic curve = 0.86-0.95). Lipidome alterations in BPD and MDD, assessed in 184 and 256 individuals, respectively, were found to be similar to those of SCZ (BPD: r = 0.89; MDD: r = 0.92; P &amp;amp;lt; 10 −79 ). Assessment of detected alterations in individuals with a first psychotic episode, as well as patients with SCZ not receiving medication, demonstrated only limited association with medication restricted to particular lipids. Conclusions and Relevance In this study, SCZ was accompanied by a reproducible profile of plasma lipidome alterations, not associated with symptom severity, medication, and demographic and environmental variables, and largely shared with BPD and MDD. This lipid alteration signature may represent a trait marker of severe psychiatric disorders, indicating its potential to be transformed into a clinically applicable testing procedure.